NPEC-caged-dopamine

Discontinued Product

NPEC-caged-dopamine (Cat. No. 3992) has been withdrawn from sale for commercial reasons.
Cat.No. 3992 - NPEC-caged-dopamine | C17H18N2O6 | CAS No. 1257326-23-0
Description: Caged dopamine
Chemical Name: (N)-1-(2-Nitrophenyl)ethylcarboxy-3,4-dihydroxyphenethylamine
Purity: ≥99% (HPLC)
Datasheet
Citations (2)
Reviews
Literature (5)

Biological Activity for NPEC-caged-dopamine

NPEC-caged-dopamine is a NPEC ((N)-1-(2-nitrophenyl)ethyl) caged version of dopamine (Cat. No 3548); releases dopamine leading to D1 receptor activation upon UV light illumination (360 nm). Induces PKA activation and c-Fos expression in cortical and striatal neurons, with striatal neurons demonstrating a significantly greater detection and sensitivity to sub-second dopamine signals as compared to cortical neurons.

Technical Data for NPEC-caged-dopamine

M. Wt 346.33
Formula C17H18N2O6
Storage Store at -20°C
Purity ≥99% (HPLC)
CAS Number 1257326-23-0
PubChem ID 90488901
InChI Key PDNNZLULXSQJGZ-UHFFFAOYSA-N
Smiles CC(OC(NCCC2=CC=C(O)C(O)=C2)=O)C1=C([N+]([O-])=O)C=CC=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for NPEC-caged-dopamine

Certificate of Analysis / Product Datasheet
Select another batch:

References for NPEC-caged-dopamine

References are publications that support the biological activity of the product.

Castro et al (2013) Striatal neurones have a specific ability to respond to phasic DA release. J.Physiol. 591 3197 PMID: 23551948

View Related Products by Product Action

View all Non-selective Dopamine Agonists

Keywords: NPEC-caged-dopamine, NPEC-caged-dopamine supplier, caged, dopamine, compounds, neurotransmitters, D, receptors, dopaminergic, Caged, Dopamine, Compounds, D1, and, D5, Receptors, Non-selective, 3992, Tocris Bioscience

2 Citations for NPEC-caged-dopamine

Citations are publications that use Tocris products. Selected citations for NPEC-caged-dopamine include:

Yapo et al (2017) Detection of phasic DA by D1 and D2 striatal medium spiny neurons. J.Physiol. 595 7451 PMID: 28782235

Castro et al (2013) Striatal neurones have a specific ability to respond to phasic DA release. J.Physiol. 591 3197 PMID: 23551948


Reviews for NPEC-caged-dopamine

There are currently no reviews for this product. Be the first to review NPEC-caged-dopamine and earn rewards!

Have you used NPEC-caged-dopamine?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


GPCR Product Listing

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Neurodegeneration Product Guide

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Dopamine Receptors Scientific Review

Dopamine Receptors Scientific Review

Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.

Parkinson's Poster

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.

Schizophrenia Poster

Schizophrenia Poster

Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.